About Hypoxanthine-guanine phosphoribosyltransferase
Hypoxanthine-guanine phosphoribosyltransferase (HPRT1) is a protein
from Homo sapiens identified by UniProt accession
P00492, 218 residues long.
MolForge cross-references it against 0 known binders and
929 disease associations.
Target properties
| Protein name | Hypoxanthine-guanine phosphoribosyltransferase |
|---|
| UniProt accession | P00492 |
|---|
| Gene | HPRT1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 218 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (929)
Diseases linked to this target (Open Targets).
- Lesch-Nyhan syndrome · score 0.85
- hypoxanthine guanine phosphoribosyltransferase partial deficiency · score 0.81
- neurodegenerative disease · score 0.44
- Dystonia · score 0.37
- neuroinflammatory disorder · score 0.37
- nephrolithiasis · score 0.35
- Nephrocalcinosis · score 0.35
- uric acid measurement · score 0.33
- genetic disorder · score 0.12
- Microcephaly · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P00492-F1 | alphafold | PREDICTED | 92.56 | — |
Amino-acid sequence (218 residues)
MATRSPGVVI SDDEPGYDLD LFCIPNHYAE DLERVFIPHG LIMDRTERLA RDVMKEMGGH HIVALCVLKG GYKFFADLLD YIKALNRNSD RSIPMTVDFI RLKSYCNDQS TGDIKVIGGD DLSTLTGKNV LIVEDIIDTG KTMQTLLSLV RQYNPKMVKV ASLLVKRTPR SVGYKPDFVG FEIPDKFVVG YALDYNEYFR DLNHVCVISE TGKAKYKA
Explore Hypoxanthine-guanine phosphoribosyltransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets